- Home
- PIM vs ALDX Comparison
PIM vs ALDX Comparison
Compare PIM & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- ALDX
- Stock Information
- Founded
- PIM 1988
- ALDX 2004
- Country
- PIM United States
- ALDX United States
- Employees
- PIM N/A
- ALDX N/A
- Industry
- PIM Finance Companies
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PIM Finance
- ALDX Health Care
- Exchange
- PIM Nasdaq
- ALDX Nasdaq
- Market Cap
- PIM 161.4M
- ALDX 160.8M
- IPO Year
- PIM N/A
- ALDX 2014
- Fundamental
- Price
- PIM $3.33
- ALDX $4.76
- Analyst Decision
- PIM
- ALDX Strong Buy
- Analyst Count
- PIM 0
- ALDX 2
- Target Price
- PIM N/A
- ALDX $9.50
- AVG Volume (30 Days)
- PIM 57.5K
- ALDX 1.2M
- Earning Date
- PIM 01-01-0001
- ALDX 07-31-2025
- Dividend Yield
- PIM 8.28%
- ALDX N/A
- EPS Growth
- PIM N/A
- ALDX N/A
- EPS
- PIM 0.05
- ALDX N/A
- Revenue
- PIM N/A
- ALDX N/A
- Revenue This Year
- PIM N/A
- ALDX N/A
- Revenue Next Year
- PIM N/A
- ALDX N/A
- P/E Ratio
- PIM $63.80
- ALDX N/A
- Revenue Growth
- PIM N/A
- ALDX N/A
- 52 Week Low
- PIM $2.90
- ALDX $1.14
- 52 Week High
- PIM $3.28
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PIM 51.79
- ALDX 78.74
- Support Level
- PIM $3.34
- ALDX $4.12
- Resistance Level
- PIM $3.35
- ALDX $4.60
- Average True Range (ATR)
- PIM 0.03
- ALDX 0.29
- MACD
- PIM 0.00
- ALDX 0.08
- Stochastic Oscillator
- PIM 63.64
- ALDX 90.91
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.